Biodexa Pharmaceuticals (Biodexa Pharmaceuticals) COGS-to-Revenue : 21.90 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Biodexa Pharmaceuticals COGS-to-Revenue?

Biodexa Pharmaceuticals's Cost of Goods Sold for the six months ended in Dec. 2023 was $2.30 Mil. Its Revenue for the six months ended in Dec. 2023 was $0.11 Mil.

Biodexa Pharmaceuticals's COGS to Revenue for the six months ended in Dec. 2023 was 21.90.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Biodexa Pharmaceuticals's Gross Margin % for the six months ended in Dec. 2023 was -2,089.52%.

Biodexa Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Biodexa Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biodexa Pharmaceuticals COGS-to-Revenue Chart

Biodexa Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

11.64

17.69

8.05

7.31

10.68

Biodexa Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															14.96	5.16	11.69	7.56	21.90

Biodexa Pharmaceuticals COGS-to-Revenue Calculation

Biodexa Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	5.148	/	0.482
	=	10.68

Biodexa Pharmaceuticals's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2.299	/	0.105
	=	21.90

Biodexa Pharmaceuticals (NAS:BDRX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Biodexa Pharmaceuticals's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	2.299 / 0.105
	=	-2,089.52 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Biodexa Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biodexa Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Biodexa Pharmaceuticals (Biodexa Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biodexa Pharmaceuticals Plc (NAS:BDRX) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

5MP:Germany

Address

1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ

Website

https://www.biodexapharma.com

Biodexa Pharmaceuticals Plc is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.